Luminex (Luminex) Retained Earnings : $92.4 Mil (As of Mar. 2021)

View and export this data going back to 2000. Start your Free Trial

What is Luminex Retained Earnings?

Retained earnings is the accumulated portion of net income that is not distributed to shareholders. Luminex's retained earnings for the quarter that ended in Mar. 2021 was $92.4 Mil.

Luminex's quarterly retained earnings declined from Sep. 2020 ($88.3 Mil) to Dec. 2020 ($83.8 Mil) but then increased from Dec. 2020 ($83.8 Mil) to Mar. 2021 ($92.4 Mil).

Luminex's annual retained earnings declined from Dec. 2018 ($103.4 Mil) to Dec. 2019 ($85.9 Mil) and declined from Dec. 2019 ($85.9 Mil) to Dec. 2020 ($83.8 Mil).

Luminex Retained Earnings Historical Data

The historical data trend for Luminex's Retained Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Luminex Retained Earnings Chart

Luminex Annual Data

Trend

Dec11

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Retained Earnings

Get a 7-Day Free Trial

68.90

87.66

103.39

85.89

83.79

Luminex Quarterly Data
	Jun16	Sep16	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21
Retained Earnings	Get a 7-Day Free Trial															82.40	90.73	88.26	83.79	92.41

Luminex Retained Earnings Calculation

Retained Earnings is the accumulated portion of net income that is not distributed to shareholders. Because the net income was not distributed to shareholders, shareholders' equity is increased by the same amount.

Of course, if a company loses, it is called retained losses, or accumulated losses.

Luminex (NAS:LMNX) Retained Earnings Explanation

Historically profitable companies sometimes have negative retained earnings. This is because they have cumulatively paid out more to shareholders than they reported in profits.

For example, in 2011, Microsoft had negative retained earnings. This does not mean the company lost more money than it made over the years. It just means it paid out more money than it earned.

If a company has negative retained earnings, investors should check the 10-year financial results. They should not assume that negative retained earnings prove a company has generally lost money in the past.

Of course, many companies with negative retained earnings have indeed lost money in the past.

Retained Earnings: Warren Buffett's Secret.

One of the most important indicators of durable competitive advantage. Net earnings can be paid out as dividends, used to buy back shares or retained for growth.

If the company loses more than it has accumulated, retained earnings is negative.

If a company isn't adding to its retained earnings, it isn't growing its net worth.

Rate of growth of retained earnings is good indicator whether it's benefiting from a competitive advantage.

Microsoft is negative because it chose to buyback stock and pay dividends.

The more earnings retained, the faster it grows and increases growth rate for future earnings.

Luminex (Luminex) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Luminex Corp (NAS:LMNX) » Definitions » Retained Earnings

Comparable Companies

Traded in Other Exchanges

N/A

Address

12212 Technology Boulevard, Suite 130, Austin, TX, USA, 78727

Website

https://www.luminexcorp.com

Luminex Corp develops, manufactures, and sells proprietary biological testing technologies and products to testing laboratories. It primarily serves the life sciences industries by selling products used by laboratory professionals and clinical laboratories in performing diagnostics, drug research and discovery, and clinical tests on patients. Luminex's market segments mainly include Infectious disease, Personalized medicine, and Human genetics. It offers various solutions in diverse markets, including clinical diagnostics, pharmaceutical drug discovery, biomedical research, genomic and proteomic research, and food safety. The vast majority of the company's revenue is earned in the United States. The products offered are xMAP Products, ARIES Products and VERIGENE Products, among others.

Executives

Harriss T Currie	officer: SVP, Finance & CFO	12212 TECHNOLOGY BOULEVARD AUSTIN TX 78727
Todd C. Bennett	officer: SVP, Global Sales & Cust Ops	12212 TECHNOLOGY BLVD. AUSTIN TX 78727
Stephen L. Eck	director	12212 TECHNOLOGY BLVD., AUSTIN TX 78727
Edward A Ogunro	director
Eric Shapiro	officer: SR VP, GLOBAL MARKETING	12212 TECHNOLOGY BLVD. AUSTIN TX 78727
Nachum Shamir	director, officer: President & CEO	12212 TECHNOLOGY BLVD, AUSTIN TX 78727
Rew Richard W. Ii	officer: SVP, Gen Counsel & Corp Secy	7000 WEST WILLIAM CANNON, BUILDING ONE, AUSTIN TX 78735
Nancy Fairchild	officer: SVP, Human Resources	12212 TECHNOLOGY BLVD. AUSTIN TX 78727
G Walter Lowenbaum	director	C/O 3D SYSTEMS CORPORATION, 333 THREE D SYSTEMS CIRCLE, ROCK HILL SC 29730
Randall Myers	officer: SVP, Global Mfg and Quality	12212 TECHNOLOGY BOULEVARD AUSTIN TX 78727
Charles J. Collins	officer: SR VP, R&D - US	12212 TECHNOLOGY BLVD. AUSTIN TX 78727
Dijuana K Lewis	director	120 MONUMENT CIRCLE, INDIANAPOLIS IN 46204
Jim D Kever	director	C/O 3D SYSTEMS, 26081 AVENUE HALL, VALENCIA CA 91355
Thomas W Erickson	director	OMEGA HEALTHCARE INVESTORS INC, 900 VICTORS WAY STE. 350, AMM ARBER MI 48108
Kenneth A Samet	director	800 KING FARM BOULEVARD, 4TH FLOOR, ROCKVILLE MD 20850